Announcements Trials
Browse Landscape

Phase

Phase 1 2Phase 2 1

Status

Recruiting 1Active not recruiting 1

Sponsor Class

NIH 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Thoracic 1Sarcoma 1Other hematologic neoplasm 1Head & Neck 1Gastrointestinal 1

Conditions

Squamous Cell Carcinoma of Head and Neck 1Solitary Fibrous Tumors 1Sarcoma 1Liposarcoma 1Leukemia, Hairy Cell 1Histiocytoma, Malignant Fibrous 1Dermatofibrosarcoma 1Colorectal Neoplasms 1Carcinoma, Non-Small-Cell Lung 1

Interventions

Specimen Handling 146pembrolizumab 120Magnetic Resonance Spectroscopy 117Cyclophosphamide 114Biopsy 97fludarabine 88Nivolumab 52Carboplatin 51Cisplatin 47Gemcitabine 46venetoclax 41Radiotherapy 41Paclitaxel 40Cetuximab 40fludarabine phosphate 39Ipilimumab 34atezolizumab 33Fluorouracil 33Bevacizumab 33Oxaliplatin 27Leucovorin 27Dexamethasone 27durvalumab 26X-Rays 25Irinotecan 25Radiation 24Cytarabine 24Azacitidine 24Injections 22Temozolomide 21

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 1 × Famotidine × 90 days × Clear all
NCT06789172 2026-05-22

INVOKE

Epkin

Phase 1 Recruiting
166 enrolled
GastrointestinalHead & NeckSarcomaThoracic

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Non-Small-Cell Lung, Liposarcoma, Sarcoma, Colorectal Neoplasms, Dermatofibrosarcoma, Histiocytoma, Malignant Fibrous, Solitary Fibrous Tumors

NCT03805932 2026-05-19

Moxetumomab Pasudotox-tdfk (Lumoxiti(TM)) and Either Rituximab (Rituxan(R)) or Ruxience for Relapsed Hairy Cell Leukemia

National Institutes of Health Clinical Center (CC)

Phase 1 Active not recruiting
18 enrolled 15 charts
Other hematologic neoplasm

Leukemia, Hairy Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡